Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Visit old site
Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 445

    Article Cited by others

REVIEW ARTICLE

Pancreatic cancer: chemotherapy and radiotherapy

Andrén-Sandberg Ĺke

Year : 2011| Volume: 3| Issue : 1 | Page no: 1-12

   This article has been cited by
 
1 UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer
Qiangsheng Hu,Yi Qin,Shunrong Ji,Wenyan Xu,Wensheng Liu,Qiqing Sun,Zheng Zhang,Mengqi Liu,Quanxing Ni,Xianjun Yu,Xiaowu Xu
Cancer Letters. 2019; 452: 226
[Pubmed]  [Google Scholar] [DOI]
2 Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells
Simone Moertl,Sarah Payer,Rosemarie Kell,Klaudia Winkler,Natasa Anastasov,Michael J. Atkinson
International Journal of Molecular Sciences. 2019; 20(13): 3259
[Pubmed]  [Google Scholar] [DOI]
3 dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer
Qiangsheng Hu,Yi Qin,Jinfeng Xiang,Wensheng Liu,Wenyan Xu,Qiqing Sun,Shunrong Ji,Jiang Liu,Zheng Zhang,Quanxing Ni,Jin Xu,Xianjun Yu,Bo Zhang
Cell Proliferation. 2018; : e12456
[Pubmed]  [Google Scholar] [DOI]
4 Complex interplay between tumor microenvironment and cancer therapy
Minhong Shen,Yibin Kang
Frontiers of Medicine. 2018;
[Pubmed]  [Google Scholar] [DOI]
5 Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles
Bhaskar Venkata Kameswara Subrahmanya Lakkakula,Batoul Farran,Saikrishna Lakkakula,Sujatha Peela,Nagendra Sastry Yarla,Pallaval Veera Bramhachari,Mohammad Amjad Kamal,Madhu Sudhana Saddala,Ganji Purnachandra Nagaraju
Seminars in Cancer Biology. 2018;
[Pubmed]  [Google Scholar] [DOI]
6 The role of FADD in pancreatic cancer cell proliferation and drug resistance
Rong Zhang,Yingting Liu,Kahina Hammache,Liangqiang He,Bo Zhu,Wei Cheng,Zi-Chun Hua
Oncology Letters. 2017; 13(3): 1899
[Pubmed]  [Google Scholar] [DOI]
7 The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens
Joanna P. MacEwan,Wes Yin,Satyin Kaura,Zeba M. Khan
Journal of Managed Care & Specialty Pharmacy. 2017; 23(2): 206
[Pubmed]  [Google Scholar] [DOI]
8 Biological determinants of radioresistance and their remediation in pancreatic cancer
Parthasarathy Seshacharyulu,Michael J Baine,Joshua J Souchek,Melanie Menning,Sukhwinder Kaur,Ying Yan,Michel M. Ouellette,Maneesh Jain,Chi Lin,Surinder K. Batra
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2017;
[Pubmed]  [Google Scholar] [DOI]
9 Synthesis of new tricyclic thiolactams as potent antitumor agent for pancreatic cancer
Takuya Okada,Daisuke Minehira,Minetatsu Takada,Hirokazu Urata,Atsushi Kato,Isao Adachi,Yukiko Kurashima,Satoshi Kaji,Tsutomu Ogura,Shigeki Chiba,Hiroyasu Esumi,Naoki Toyooka
Bioorganic & Medicinal Chemistry Letters. 2016; 26(11): 2577
[Pubmed]  [Google Scholar] [DOI]
10 Radiation dose responses for chemoradiation therapy of pancreatic cancer: An analysis of compiled clinical data using biophysical models
Ion C. Moraru,An Tai,Beth Erickson,X. Allen Li
Practical Radiation Oncology. 2013;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article